PDE5A and melanoma: Later, a large UK-based primary care database, with 145,104 men who were prescribed a PDE5 inhibitor and 560,933 matched controls, was examined, but the findings showed no evidence of a positive association between PDE5 inhibitor exposure and melanoma risk after matching or adjusting for key potential confounders [271].